Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(2.19)
# 2,483
Out of 4,810 analysts
126
Total ratings
35.14%
Success rate
-4.37%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $7.62 | +556.17% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $1.96 | +920.41% | 2 | Mar 25, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $34.85 | +172.60% | 10 | Feb 21, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $168.91 | +27.29% | 5 | Feb 20, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $220 → $260 | $155.50 | +67.20% | 2 | Feb 18, 2025 | |
| SEPN Septerna | Reiterates: Overweight | $50 | $6.07 | +723.72% | 2 | Feb 11, 2025 | |
| SPRO Spero Therapeutics | Downgrades: In-Line | $5 | $0.70 | +613.27% | 4 | Dec 20, 2024 | |
| JANX Janux Therapeutics | Reiterates: Overweight | $200 | $28.95 | +590.85% | 6 | Dec 11, 2024 | |
| TRML Tourmaline Bio | Reiterates: Overweight | $25 | $14.09 | +77.43% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Reiterates: Overweight | n/a | $1.12 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $5.91 | +999.83% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $14.47 | +107.33% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.78 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.98 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $29.78 | +202.22% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.20 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $71.03 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.34 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.18 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.53 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $60.30 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.27 | +5,451.44% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $26.91 | +96.95% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $33.44 | +94.38% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $39.59 | +51.55% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.17 | +4,191.85% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $20.06 | +273.88% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $1.10 | +354.55% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.24 | +787.10% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $94.89 | +37.00% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $571.06 | +33.09% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $11.00 | +36.36% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $7.74 | +610.59% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.17 | +2,464.10% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.24 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $6.33 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $322.32 | -22.44% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3,500 → $4,600 | $4.76 | +96,538.66% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $59.22 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $28.68 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.19 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $13.27 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $9.17 | +139.91% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.73 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $59.67 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $179.10 | -46.96% | 1 | Aug 17, 2017 |
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $7.62
Upside: +556.17%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $1.96
Upside: +920.41%
BridgeBio Pharma
Feb 21, 2025
Reiterates: Overweight
Price Target: $95
Current: $34.85
Upside: +172.60%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $168.91
Upside: +27.29%
Ascendis Pharma
Feb 18, 2025
Maintains: Outperform
Price Target: $220 → $260
Current: $155.50
Upside: +67.20%
Septerna
Feb 11, 2025
Reiterates: Overweight
Price Target: $50
Current: $6.07
Upside: +723.72%
Spero Therapeutics
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $0.70
Upside: +613.27%
Janux Therapeutics
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $28.95
Upside: +590.85%
Tourmaline Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $14.09
Upside: +77.43%
Zura Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.12
Upside: -
Nov 19, 2024
Reiterates: Overweight
Price Target: $65
Current: $5.91
Upside: +999.83%
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $14.47
Upside: +107.33%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.78
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.98
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $29.78
Upside: +202.22%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.20
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $71.03
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.34
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.18
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.53
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $60.30
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.27
Upside: +5,451.44%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $26.91
Upside: +96.95%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $33.44
Upside: +94.38%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $39.59
Upside: +51.55%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.17
Upside: +4,191.85%
May 6, 2024
Reiterates: Overweight
Price Target: $75
Current: $20.06
Upside: +273.88%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $1.10
Upside: +354.55%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.24
Upside: +787.10%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $94.89
Upside: +37.00%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $571.06
Upside: +33.09%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $11.00
Upside: +36.36%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $7.74
Upside: +610.59%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.17
Upside: +2,464.10%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.24
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $6.33
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $322.32
Upside: -22.44%
Jun 19, 2018
Upgrades: Outperform
Price Target: $3,500 → $4,600
Current: $4.76
Upside: +96,538.66%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $59.22
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $28.68
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.19
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $13.27
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $9.17
Upside: +139.91%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $8.73
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $59.67
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $179.10
Upside: -46.96%